ribosomal protein L10Genealiases: AUTSX5 · DXS648 · DXS648E · L10 · MRXS35 · NOV
Q-omics provides the consensus-scored RPL10 profile across patient tissues and cancer cell-line models. RPL10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL10 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL10 protein abundance shows 24,109 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRP, KIRC, and CCRCC as cancer lineages where RPL10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10 survival associations across molecular data types. RPL10 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10 RNA expression–survival associations across cancer types. High RPL10 expression shows unfavorable associations in KIRP, ACC, PAAD and KICH, but favorable associations in UVM and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL10 RNA expression.
This table summarizes RPL10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPL10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10 shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, LIHC, COAD and KIRP. The KIRC box plot shows higher RPL10 RNA expression in tumor versus normal tissue (log2 FC = +1.279, t-test p < 0.001).
This table shows molecular features associated with RPL10 in patient tissues and cancer cell lines. In patient samples, RPL10 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
